US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

AdvisorShares Psychedelics ETF

26.80

+0.90003.47%

Volume:57.05K

Turnover:1.51M

Market Cap:60.17M

PE:- -

High:26.80

Open:26.11

Low:26.11

Close:25.90

52wk High:26.80

52wk Low:15.63

Shares:2.24M

Float Shares:2.24M

Volume Ratio:0.71

T/O Rate:2.54%

Dividend:1.70

Dividend Rate:6.36%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Nxera to Book US$10m Milestone as FDA Clears Phase 2 Alzheimer’s Drug

FireFly announces successful A$190m capital raising to fund development and resource growth

NRX Pharmaceuticals Price Target Maintained with a $45.00/Share by HC Wainwright & Co.

Baiyunshan Pharmaceutical Subsidiary Gets Supplementary Drug Approval for Low Blood Pressure Injection

MT Newswires Live

Alkermes’ Alixorexton Posts Positive Phase 2 Vibrance-1 Results in Narcolepsy Type 1 Study

The Lancet Neurology Publishes Data from Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults with Narcolepsy Type 1

THOMSON REUTERS

Savara announces presentations of Results from Phase 3 trial of Molgramostim

Amgen Extends MariTide Study In Obesity And Diabetes, Keeping Investor Focus On Long-Term Potential

Biogen Expands Autoimmune Pipeline With New Graves’ Disease Trial

AbbVie’s Emraclidine Schizophrenia Study Ends Early: What Investors Need to Know Now

CStone Gains Rapid China IND Approval for EGFR/HER3 ADC CS5007

Bayer’s Adempas Trial Update: What a Terminated Heart-Lung Study Means for BAYRY

How COMPASS Pathways’ VA Psilocybin Trial (CMPS) Has Reframed Its Veteran Mental Health Ambitions

Simply Wall St.

Pacific Edge shareholders back governance moves and capital raisings at 2026 meeting

Moderna Stock (MRNA) Soars 133%; Five-Star William Blair Analyst Says Strong Cancer Data Could Be a Game-Changer

Cullinan, Taiho say results of Phase 3 trial selected for presentation

Biodexa recruits 87 of 168 subjects in Serenta Phase 3 eRapa polyposis trial

Video: Moderna skyrockets after cancer vaccine shows promise in Phase 3 trial

Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP

Amylyx announces Lucidity Phase 3 trial met primary endpoint

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/PSIL/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PSIL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSIL\",,,,,undefined,":{"symbol":"PSIL","market":"US","secType":"STK","nameCN":"AdvisorShares Psychedelics ETF","latestPrice":26.8,"timestamp":1787688000000,"preClose":25.9,"halted":0,"volume":57049,"delay":0,"changeRate":0.03474903474903483,"floatShares":2244976,"shares":2244976,"eps":0,"marketStatus":"Pre-Mkt","change":0.9,"latestTime":"08-26 07:11:11 EDT","open":26.11,"high":26.8,"low":26.11,"amount":1510627.28403,"amplitude":0.026641,"askPrice":29.18,"askSize":100,"bidPrice":23.32,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787751000000},"marketStatusCode":1,"adr":0,"exchange":"ARCA","adjPreClose":26.8,"sharesOutstanding":1184976,"nav":25.732,"aum":57766911.89,"dividendRate":0.063616,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":26.88,"preClose":26.8,"latestTime":"19:32 EDT","volume":216,"amount":5804.83,"timestamp":1787700759051,"change":0.08,"changeRate":0.002985,"amplitude":0.002985},"volumeRatio":0.7069163774217114,"impliedVol":0.388,"impliedVolPercentile":0.688},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSIL\",,,,,undefined,":{"symbol":"PSIL","floatShares":2244976,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.7069163774217114,"shares":2244976,"dividePrice":1.7049,"high":26.8,"amplitude":0.026641,"preClose":25.9,"low":26.11,"week52Low":15.6348,"pbRate":"--","week52High":26.8,"institutionHeld":0,"latestPrice":26.8,"eps":0,"divideRate":0.063616,"volume":57049,"delay":0,"ttmEps":0,"open":26.11,"prevYearClose":17.17,"prevWeekClose":25.86,"prevMonthClose":23.5,"prevQuarterClose":24.05,"fiveDayClose":26.2,"twentyDayClose":23.14,"sixtyDayClose":21.72},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PSIL\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"PSIL","amount":1.68387,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-29","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-29"},{"date":"2025-09-22","symbol":"PSIL","amount":0.02007,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-29","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-29"},{"date":"2025-06-23","symbol":"PSIL","amount":0.01191,"announcedDate":"2025-06-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-27"},{"date":"2025-03-21","symbol":"PSIL","amount":0.16343,"announcedDate":"2025-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-21","defaultRemindTime":1742563800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-28","payableDate":"2025-03-21","currency":"USD","dateTimestamp":1742529600000,"payDate":"2025-03-28"},{"date":"2024-12-23","symbol":"PSIL","amount":0.05477,"announcedDate":"2024-12-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-30","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-30"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PSIL\",market:\"US\",,,undefined,":[{"executeDate":"2022-09-26","recordDate":"2022-09-27","paymentDate":"2022-09-30","value":0.05421,"currency":"USD"},{"executeDate":"2023-09-25","recordDate":"2023-09-26","paymentDate":"2023-09-29","value":0.00336,"currency":"USD"},{"executeDate":"2024-09-23","recordDate":"2024-09-23","paymentDate":"2024-09-30","value":0.1087,"currency":"USD"},{"executeDate":"2024-12-23","recordDate":"2024-12-23","paymentDate":"2024-12-30","value":0.05477,"currency":"USD"},{"executeDate":"2025-03-21","recordDate":"2025-03-21","paymentDate":"2025-03-28","value":0.16343,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PSIL\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PSIL\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662795913","title":"Nxera to Book US$10m Milestone as FDA Clears Phase 2 Alzheimer’s Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2662795913","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662795913?lang=en_us&edition=fundamental","pubTime":"2026-08-26 15:52","pubTimestamp":1787730745,"startTime":"0","endTime":"0","summary":"Sosei Group ( ($JP:4565) ) has provided an update. Nxera Pharma’s partner Neurocrine Biosciences has secured FDA IND acceptance for a Phase 2 trial...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nxera-to-book-us10m-milestone-as-fda-clears-phase-2-alzheimers-drug?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nxera-to-book-us10m-milestone-as-fda-clears-phase-2-alzheimers-drug?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4585","IND","LABU","PSIL","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662067764","title":"FireFly announces successful A$190m capital raising to fund development and resource growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2662067764","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662067764?lang=en_us&edition=fundamental","pubTime":"2026-08-26 11:53","pubTimestamp":1787716380,"startTime":"0","endTime":"0","summary":"Proceeds will be used for early works, long-lead items and resource drilling FireFly has received firm commitments to raise ~A$180m (before costs) via an Australian institutional placement and Canadia","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/26/3351065/0/en/firefly-announces-successful-a-190m-capital-raising-to-fund-development-and-resource-growth.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DBB","XME","LIFE","BMO","UYM","BK4173","BK4207","BK4535","BK4563","PICK","BK4139","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662560967","title":"NRX Pharmaceuticals Price Target Maintained with a $45.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2662560967","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662560967?lang=en_us&edition=fundamental","pubTime":"2026-08-26 00:58","pubTimestamp":1787677080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NRXP/analyst-ratings","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","NRXP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662078059","title":"Baiyunshan Pharmaceutical Subsidiary Gets Supplementary Drug Approval for Low Blood Pressure Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2662078059","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662078059?lang=en_us&edition=fundamental","pubTime":"2026-08-25 17:18","pubTimestamp":1787649510,"startTime":"0","endTime":"0","summary":"Guangzhou Baiyunshan Pharmaceutical Holdings  subsidiary Guangzhou Baiyunshan Mingxing Pharmaceutical received supplementary drug approval from China's National Medical Products Administration for its norepinephrine bitartrate injection.The drug approval covers drug prescription and manufacturing processes, registration, packaging materials, and revision of drug instructions.The drug is indicated for low blood pressure control.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0183","BK0097","BK0188","BK0096","BK0012","TBXU","BK0070","PSIL","BK0028","BK0196","600332","BK0239","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662620199","title":"Alkermes’ Alixorexton Posts Positive Phase 2 Vibrance-1 Results in Narcolepsy Type 1 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2662620199","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662620199?lang=en_us&edition=fundamental","pubTime":"2026-08-25 06:30","pubTimestamp":1787610625,"startTime":"0","endTime":"0","summary":"Alkermes’ alixorexton posts positive Phase 2 Vibrance-1 results in narcolepsy type 1 studyAlkermes reported publication of positive Phase 2 Vibrance-1 results for alixorexton in adults with narcolepsy type 1 in The Lancet Neurology.Results were previously announced, not newly presented, showing improved daytime wakefulness and sleepiness measures versus placebo.Study also indicated reduced cataplexy at one dose, with broader patient-reported benefits in daily functioning.Safety profile appeared generally well tolerated, with mostly mild-to-moderate adverse events and no serious treatment-emergent events reported.Positive Phase 2 readouts supported the launch of the global Phase 3 Brilliance program testing once-daily and split-dose regimens in narcolepsy types 1 and 2.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purpos","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nNDL56tjq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALKS","BK4139","FBT","PSCH","PSIL","IBRN","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662201993","title":"The Lancet Neurology Publishes Data from Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults with Narcolepsy Type 1","url":"https://stock-news.laohu8.com/highlight/detail?id=2662201993","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662201993?lang=en_us&edition=fundamental","pubTime":"2026-08-25 06:30","pubTimestamp":1787610600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nTUA7VQ936:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","FBT","MEDX","PSIL","PSCH","IBRN","ALKS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662206573","title":"Savara  announces presentations of Results from Phase 3 trial of Molgramostim","url":"https://stock-news.laohu8.com/highlight/detail?id=2662206573","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662206573?lang=en_us&edition=fundamental","pubTime":"2026-08-25 04:10","pubTimestamp":1787602218,"startTime":"0","endTime":"0","summary":"Savara (SVRA) announced the acceptance of one oral presentation and two poster presentations on data from the Phase 3 IMPALA-2 clinical trial at th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/savara-announces-presentations-of-results-from-phase-3-trial-of-molgramostim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/savara-announces-presentations-of-results-from-phase-3-trial-of-molgramostim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GDOC","IDNA","BK4139","BBC","SVRA","MEDX","NVIB","PSIL","HYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662729270","title":"Amgen Extends MariTide Study In Obesity And Diabetes, Keeping Investor Focus On Long-Term Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2662729270","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662729270?lang=en_us&edition=fundamental","pubTime":"2026-08-25 00:31","pubTimestamp":1787589063,"startTime":"0","endTime":"0","summary":"Amgen Inc ($AMGN) announced an update on their ongoing clinical study. Amgen Inc. is moving ahead with MARITIME-2-EXTENSION, a Phase 3 trial that t...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/amgen-extends-maritide-study-in-obesity-and-diabetes-keeping-investor-focus-on-long-term-potential?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/amgen-extends-maritide-study-in-obesity-and-diabetes-keeping-investor-focus-on-long-term-potential?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBC","BK4566","IE0009355771.USD","IE00BJT1NW94.SGD","TBXU","LU0889565916.HKD","LU1983299246.USD","BBH","LU2242652126.USD","IBBQ","LU1061106388.HKD","LU0122379950.USD","LU0320765992.SGD","BK4533","LU2242646821.SGD","AMGN","SG9999001440.SGD","IE0002141913.USD","IE00BJJMRZ35.SGD","IBB","LU0868494617.USD","BK4585","LU1057294990.SGD","LU2112291526.USD","PBE","BK4139","LU2089984988.USD","LU0289739699.SGD","IE00B2B36J28.USD","PSIL","BIB","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","LU1571399168.USD","PJP","LU0058720904.USD","LU2468319806.SGD","BK4588","LU0109394709.USD","BK4534","BK4599","LU1023059063.AUD","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661294871","title":"Biogen Expands Autoimmune Pipeline With New Graves’ Disease Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2661294871","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661294871?lang=en_us&edition=fundamental","pubTime":"2026-08-22 00:33","pubTimestamp":1787330033,"startTime":"0","endTime":"0","summary":"Biogen Inc. ($BIIB) announced an update on their ongoing clinical study. Biogen Inc. has launched a Phase 2 trial testing felzartamab in adults wit...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/biogen-expands-autoimmune-pipeline-with-new-graves-disease-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/biogen-expands-autoimmune-pipeline-with-new-graves-disease-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BMED","BK4532","BBC","LU0320765992.SGD","IE00B19Z9P08.USD","IE00B19Z9Z06.USD","LU0109394709.USD","LU0234570918.USD","PSIL","PBE","BK4139","BK4588","BK4585","LU0889565916.HKD","IE00B894F039.SGD","BIIB","BK4533"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661294820","title":"AbbVie’s Emraclidine Schizophrenia Study Ends Early: What Investors Need to Know Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2661294820","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661294820?lang=en_us&edition=fundamental","pubTime":"2026-08-22 00:30","pubTimestamp":1787329825,"startTime":"0","endTime":"0","summary":"Abbvie ($ABBV) announced an update on their ongoing clinical study. AbbVie’s long-term Phase 2 trial NCT05443724, titled “A 52-week, Phase 2, Open-...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/abbvies-emraclidine-schizophrenia-study-ends-early-what-investors-need-to-know-now?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/abbvies-emraclidine-schizophrenia-study-ends-early-what-investors-need-to-know-now?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBC","SG9999003800.SGD","IE00BN8TJ469.HKD","GLAM","IE00BJT1NW94.SGD","IE00B19Z3B42.SGD","BK4534","LU0689626769.HKD","LU1003077747.HKD","PPH","MEDX","LU0861579265.USD","IE0004445239.USD","LU1934455863.HKD","LU0708994859.HKD","BK4588","LU1929549753.HKD","LU1093756168.USD","AGNG","LU1244550494.USD","ABBV","BK4550","LU0943347566.SGD","SG9999001440.SGD","LU0310799852.SGD","IXJ","LU0256863811.USD","LU0795875086.SGD","FHLC","LU2023251221.USD","ISBC","IYH","FTXH","IE00B4R5TH58.HKD","LU1267930490.SGD","PSIL","JDOC","LU0029864427.USD","LU1551013342.USD","LU2237443895.HKD","TRUH","LU0432979614.USD","XLV","LU0158827948.USD","PJP","LU0234570918.USD","IE000F7OJYX1.SGD","LU1989772840.SGD","RXL","VHT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661302932","title":"CStone Gains Rapid China IND Approval for EGFR/HER3 ADC CS5007","url":"https://stock-news.laohu8.com/highlight/detail?id=2661302932","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661302932?lang=en_us&edition=fundamental","pubTime":"2026-08-21 06:07","pubTimestamp":1787263635,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals ( ($HK:2616) ) just unveiled an announcement. CStone Pharmaceuticals has secured rapid investigational new drug approval in ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cstone-gains-rapid-china-ind-approval-for-egfr-her3-adc-cs5007?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cstone-gains-rapid-china-ind-approval-for-egfr-her3-adc-cs5007?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4231","PSIL","BK4080","TBXU","IND","ADC","NETL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661975236","title":"Bayer’s Adempas Trial Update: What a Terminated Heart-Lung Study Means for BAYRY","url":"https://stock-news.laohu8.com/highlight/detail?id=2661975236","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661975236?lang=en_us&edition=fundamental","pubTime":"2026-08-21 00:30","pubTimestamp":1787243423,"startTime":"0","endTime":"0","summary":"Bayer AG ($BAYRY) announced an update on their ongoing clinical study. Study Overview: Bayer has updated results from a terminated Phase 2 trial of...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bayers-adempas-trial-update-what-a-terminated-heart-lung-study-means-for-bayry?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bayers-adempas-trial-update-what-a-terminated-heart-lung-study-means-for-bayry?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BAYRY","PSIL","BBC","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660238944","title":"How COMPASS Pathways’ VA Psilocybin Trial (CMPS) Has Reframed Its Veteran Mental Health Ambitions","url":"https://stock-news.laohu8.com/highlight/detail?id=2660238944","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660238944?lang=en_us&edition=fundamental","pubTime":"2026-08-20 21:39","pubTimestamp":1787233192,"startTime":"0","endTime":"0","summary":"Earlier in August 2026, COMPASS Pathways plc announced it is working with the U.S. Department of Veterans Affairs on PIVOT, a multi-site randomized controlled trial testing its COMP360 psilocybin in veterans with treatment-resistant depression, including those with concurrent PTSD, while also presenting at Stifel’s 2026 Biotech Summer Summit in Newport, Rhode Island.\nThe VA collaboration highlights federal interest in evaluating COMP360 within a large veteran population, potentially...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cmps/compass-pathways/news/how-compass-pathways-va-psilocybin-trial-cmps-has-reframed-i","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cmps/compass-pathways/news/how-compass-pathways-va-psilocybin-trial-cmps-has-reframed-i","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CMPS","BK4139","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660240325","title":"Pacific Edge shareholders back governance moves and capital raisings at 2026 meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2660240325","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660240325?lang=en_us&edition=fundamental","pubTime":"2026-08-20 13:18","pubTimestamp":1787203086,"startTime":"0","endTime":"0","summary":"Pacific Edge Limited ( ($NZ:PEB) ) has issued an announcement. Shareholders of cancer diagnostics company Pacific Edge approved all six resolutions...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pacific-edge-shareholders-back-governance-moves-and-capital-raisings-at-2026-meeting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pacific-edge-shareholders-back-governance-moves-and-capital-raisings-at-2026-meeting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL","PEB.NZ","BMED","BK8033"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660422820","title":"Moderna Stock (MRNA) Soars 133%; Five-Star William Blair Analyst Says Strong Cancer Data Could Be a Game-Changer","url":"https://stock-news.laohu8.com/highlight/detail?id=2660422820","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660422820?lang=en_us&edition=fundamental","pubTime":"2026-08-20 00:16","pubTimestamp":1787156173,"startTime":"0","endTime":"0","summary":"Moderna ($MRNA) skyrocketed 133% on Wednesday after new data from a cancer vaccine Phase 3 trial showed strong results. Today’s gain marks one of t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/moderna-stock-mrna-soars-133-five-star-william-blair-analyst-says-strong-cancer-data-could-be-a-game-changer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/moderna-stock-mrna-soars-133-five-star-william-blair-analyst-says-strong-cancer-data-could-be-a-game-changer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4501","IDNA","BK4533","BBC","BK4551","WDNA","BK4534","BK4568","MRNX","LGHT","PSIL","BK4588","MRNY","BK4585","BK4548","GNOM","BK4532","MRNA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660422315","title":"Cullinan, Taiho say results of Phase 3 trial selected for presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2660422315","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660422315?lang=en_us&edition=fundamental","pubTime":"2026-08-20 00:10","pubTimestamp":1787155816,"startTime":"0","endTime":"0","summary":"Taiho Oncology and Cullinan Therapeutics (CGEM) announced that results from the planned interim analysis of the Phase 3 REZILIENT3 trial have been ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cullinan-taiho-say-results-of-phase-3-trial-selected-for-presentation-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cullinan-taiho-say-results-of-phase-3-trial-selected-for-presentation-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CGEM","BBC","BK4139","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660538426","title":"Biodexa recruits 87 of 168 subjects in Serenta Phase 3 eRapa polyposis trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2660538426","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660538426?lang=en_us&edition=fundamental","pubTime":"2026-08-19 21:36","pubTimestamp":1787146574,"startTime":"0","endTime":"0","summary":"Biodexa Pharmaceuticals (BDRX) announced that it has exceeded the half-way point in the recruitment of subjects in its registrational Phase 3 trial...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biodexa-recruits-87-of-168-subjects-in-serenta-phase-3-erapa-polyposis-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biodexa-recruits-87-of-168-subjects-in-serenta-phase-3-erapa-polyposis-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BDRX","PSIL","BBC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660425479","title":"Video: Moderna skyrockets after cancer vaccine shows promise in Phase 3 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2660425479","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660425479?lang=en_us&edition=fundamental","pubTime":"2026-08-19 21:15","pubTimestamp":1787145349,"startTime":"0","endTime":"0","summary":"The Fly has brought its to-the-moment stock market reporting to YouTube! Subscribe if you want to know how the markets will open, which stocks will...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/video-moderna-skyrockets-after-cancer-vaccine-shows-promise-in-phase-3-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/video-moderna-skyrockets-after-cancer-vaccine-shows-promise-in-phase-3-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660421486","title":"Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP","url":"https://stock-news.laohu8.com/highlight/detail?id=2660421486","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660421486?lang=en_us&edition=fundamental","pubTime":"2026-08-19 20:30","pubTimestamp":1787142600,"startTime":"0","endTime":"0","summary":"August 19, 2026 Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP 87 subjects, over 50% of target, recruited Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” o","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/19/3347617/0/en/biodexa-announces-major-milestone-for-its-serenta-registrational-phase-3-trial-in-fap.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBC","BK4195","BK4211","PSIL","PFS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660461075","title":"Amylyx announces Lucidity Phase 3 trial met primary endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2660461075","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660461075?lang=en_us&edition=fundamental","pubTime":"2026-08-18 19:06","pubTimestamp":1787051213,"startTime":"0","endTime":"0","summary":"Amylyx (AMLX) Pharmaceutical announced topline results from Lucidity, a 78-participant, multicenter, randomized, double-blind, placebo-controlled P...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/amylyx-announces-lucidity-phase-3-trial-met-primary-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/amylyx-announces-lucidity-phase-3-trial-met-primary-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AMLX","BK4007","PSIL","BBC"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}